Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SFA-002 in Chronic Plaque Psoriasis
NCT05642182Phase 1Recruiting
- Sponsor
- SFA Therapeutics
- Start
- Mar 2022
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of SFA-002 in plaque psoriasis (2 arms), sponsored by SFA Therapeutics. Primary endpoints: Safety and adverse events at 24 weeks and Psoriasis Area and Severity Index at 24 weeks. Started Mar 2022; status: recruiting.
02
Drugs
SFA-002
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT05642182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05642182.